Harrow Health, a Nashville-based eyecare pharmaceutical company, announced its focus on ophthalmic therapies for the discovery, development, and commercialization of its products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. Its portfolio includes several ophthalmic medicines, such as IOPIDINE, MOXEZA, and MAXITROL eye drops, as well as newer products IHEEZO, a chloroprocaine hydrochloride ophthalmic gel, ILEVRO, NEVANAC, and VIGAMOX, non-steroidal and anti-inflammatory eye drops used post-cataract surgery or to treat bacterial conjunctivitis. Additionally, the company distributes MAXIDEX, a steroid eye drop, and TRIESENCE, a steroid injection treatment for ophthalmic diseases. Furthermore, Harrow Health is developing a new drug candidate, MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. Previously known as Imprimis Pharmaceuticals, the company changed its name to Harrow Health in December 2018.
Harrow Health's ticker is HROW
The company's shares trade on the NASDAQ stock exchange
They are based in Nashville, Tennessee
There are 51-200 employees working at Harrow Health
It is harrowinc.com
Harrow Health is in the Healthcare sector
Harrow Health is in the Drug Manufacturers - Other industry
The following five companies are Harrow Health's industry peers: